Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neurofibromatosis 1 2Ovarian Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Breast Neoplasms 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Bevacizumab 35Paclitaxel 31Carboplatin 24pembrolizumab 23Specimen Handling 21Magnetic Resonance Spectroscopy 19Gemcitabine 18olaparib 16liposomal doxorubicin 16Cyclophosphamide 15fludarabine 12Topotecan 12Biopsy 12niraparib 11Cisplatin 10Taxes 8Nivolumab 8Immunoglobulin G 8Fulvestrant 8Disulfides 8Doxorubicin 7aldesleukin 6Surveys and Questionnaires 6palbociclib 5Oxaliplatin 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Acetylcysteine × 90 days × Clear all
NCT04520139 2026-04-29

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

University of California, Irvine

Phase 1/2 Not yet recruiting
102 enrolled
Gynecologic

Chemotherapy-Related Cognitive Impairment, Ovarian Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡